Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors.
Tumor-associated antigens (TAA) provide appropriate targets for selective manipulation of the patient's immune response in the immunotherapy of cancer. Active specific immunotherapy utilizing antiidiotypic antibodies to anti-TAA antibodies has been implemented in phase I clinical trials both in patients with colorectal carcinoma and in those with melanoma. The theoretical basis for immunotherapy with antiidiotypic antibodies, the results of these clinical trials, and an evaluation of appropriate parameters for future clinical trials of active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors are reviewed.
O'Connell
M J
MJ
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.
Chen
Z J
ZJ
Yang
H
H
Yamada
M
M
Massaro
M
M
Mittelman
A
A
Ferrone
S
S
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy*; D004341:Drug Evaluation; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000628:therapy*; D012004:Rectal Neoplasms / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm